AstraZeneca PLC (AZN)vsNeuphoria Therapeutics Inc (NEUP)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
NEUP
Neuphoria Therapeutics Inc
$5.27
+1.54%
HEALTHCARE · Cap: $27.76M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 391841% more annual revenue ($58.74B vs $14.99M). AZN leads profitability with a 17.4% profit margin vs -37.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
NEUP
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+66.4%
Fair Value
$11.93
Current Price
$5.27
$6.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a value stock while NEUP is a turnaround play — different risk/reward profiles.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 33/100), backed by strong 17.4% margins. NEUP offers better value entry with a 66.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is a pioneering biotechnology firm focused on developing groundbreaking therapies for mental health disorders through the use of psychedelic compounds and innovative drug delivery mechanisms. The company is dedicated to translating advanced research into effective treatments for significant unmet needs within the mental health space, thereby positioning itself as a frontrunner in the burgeoning psychedelic therapy market. With a strong pipeline of preclinical candidates, Neuphoria represents a compelling investment opportunity for institutional investors keen on engaging with emerging biotech trends poised to reshape mental health care. Its commitment to transformative therapeutic solutions underscores its potential to significantly impact the future landscape of mental health treatment.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?